Companies › Translational Sciences
1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Cardiovascular; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TS23 Monoclonal antibody to α2-antiplasmin | SERPINF2 | Phase 2 | Pulmonary Embolism; Ischemic Stroke | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05408546 | TS23 | Phase 2 | Pulmonary Embolism | Cardiovascular | Nov 2026 |
| NCT05948566 | TS23 | Phase 2 | Ischemic Stroke | Neurology | Jul 2028 |
–
Ever Neuro Pharma AMO Pharma Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) Edgewise Therapeutics CSPC Mingfule Pharmaceutical (Guangzhou)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.